Related Experiment Video
Updated: Aug 23, 2025

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
Published on: May 10, 2022
[Research Progress of Ubiquitin Proteasome Inhibitors in Acute Myeloid Leukemia]
Fang-Nan Xiao1, Ming-Ying Zhang1, Yuan Zhou1
1State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Institute of Hematology & Blood Diseases Hospital,CAMS and PUMC,Tianjin 300020,China.
Abstract:
Ubiquitin-proteasome system (UPS) plays an essential role in eukaryotic protein cycle,the dysregulation of which can lead to tumorigenesis.Increased activities of UPS have been observed in the patients with cancers including leukemia.UPS inhibitors can kill cancer cells by affecting ubiquitin-ligating enzyme E3,deubiquitinase,and protein degradation active sites of UPS.Therefore,UPS inhibitors have emerged as an important therapy for treating hematological malignancies,while they are rarely applied in the treatment of acute myeloid leukemia.This paper summarizes the research progress in the inhibitors affecting the protein ubiquitination at different stages of acute myeloid leukemia,aiming to provide new clues for the clinical treatment of acute myeloid leukemia.

